• Record revenue of $60.7m, up 13% (+8% in constant currency)
• EBITDA of $7.8m, up 35% from 1H FY25
• Expanded manufacturing capacity by over 20%

SomnoMed Limited (ASX 'SOM' or the Company), the leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), is pleased to provide its 1H FY26 half year results for the period ended 31 December 2025 (1H FY26). The Company reported record revenue of $60.7m, up 13% (+8% in constant currency) on 1H FY25. EBITDA1 of $7.8m, up 35% from $5.8 million in 1H FY25, was supported by continued drive for operating leverage, with budgeted investments weighted more to 2H FY26. Gross margin remained broadly consistent at 61.3% versus 61.6% in 1H FY25. Capex spend of $3.4m versus $1.4m in 1H FY25 reflected planned manufacturing investment to support growth and meet year-end peak demand. The Company expanded manufacturing capacity by over 20% ahead of year-end peak demand, reducing reliance on staff and facility overtime. SomnoMed also strengthened its leadership team through the appointment of a Chief Marketing Officer and a newly created role of Chief Transformation Officer.

SomnoMed reaffirms its FY26 guidance of: revenue of between $119m and $126m, EBITDA of between $10m and $12m, and capex spend of between $6m and $8m.

With a large global population affected by obstructive sleep apnea and SomnoMed's established leadership in oral appliance therapy, the Company remains focused on disciplined execution and positioning the business for sustainable growth.